People with diabetes who get flu are 3 times more likely to be hospitalized 6 times more likely to die
LaSalud.mx / PacienteDiabetico.mx .- Currently, 11.5 million people live with diabetes in Mexico[i], A figure that has increased in recent years, since in the period between 2006 and 2012 the increase was 31.4%[ii]. For this reason, as part of World Diabetes Day, the Mexican Diabetes Association called on the population to take preventive measures to help the patient control their condition.
Diabetes is the leading cause of death in Mexico and type 2 is the most common cause of the disease. Being overweight, obese, an inactive lifestyle, as well as the history of a first degree relative are some of the major risk factors for the development of this type of diabetes.
President of the Mexican Diabetes Association Gabriella Alred noted that "it is essential that a patient with diabetes has control, since over time, high levels of glucose in the blood cause damage to many tissues in the body.The body, causing health complications, which can In Mexico, the use of insulin is delayed and determined only in 8.8% of cases requiring combination with other drugs, and 11.1% as treatment only, compared to international standards which must be large From 20%[iii]"
(9.9%), ulcers (9.14%), visual impairment And amputations (5.5%)[iv].
"At this time of the year, people with diabetes and hypertension are a risk group that needs to be vaccinated against influenza at the beginning of each season to avoid complications that can be fatal because of their condition," said Dr. Alejandrina Malcara, medical director of Sanofi Pasteur, Mexico. , In case of contamination. 88% of the confirmed cases of influenza in the 2017-2018 season occurred in people unvaccinated[v]"
Dr. Patricia Cervantes, director of medical medicine for the flu in Sanofi-Pasteur, Latin America, has reinforced the message of the vaccine, since people with diabetes who have the flu are 3 times more likely to be hospitalized and 6 times more likely to die. Sudden heart failure, heart failure, myocardial infarction and influenza pneumonia.[vi].
"Thanks to medical innovations today, we can rely on new basic insulin, which focuses on reducing the risk of hypoglycemia, improving metabolic activity and allowing better control of the patient's weight," said Dr. Maria Elena Snowo, director of medicine for diabetes in Sanofi, Mexico.
Treatments such as insulin U300, the new gold standard, allow glycemic control for up to 36 hours and lower risk of nightly hypoglycaemia, providing a more stable profile than traditional insulin. The new generation of basal insulin achieves a 20% reduction in the metabolic activity fluctuation during the day compared with other insulin.
On the other hand, the synergy of glargine insulin with lixisenatide, representing the union of two powerful antideabetic drugs injected in one dose per day, is now available in the market. This treatment is indicated for the treatment of type 2 diabetes in adults who have not achieved glycemic control with any other type of treatment and is an innovative therapeutic option that provides comprehensive glycemic control that results in 7 out of 10 control targets, affecting both basal glucose and post-meal glucose.
"The treatment of diabetes involves learning to understand the disease, as well as behavioral changes, the use of multiple medications, the frequency of medical assessments and the participation of experts in cooperation with the family and the surrounding community." So in Sanofi we work from a comprehensive perspective of diabetes, understanding that every patient has a different reality "Concluded Dr. Snudo.
[iii] Barquera, Simón, et.al. (2013). Diabetes in Mexico: The cost and management of diabetes and its complications and challenges to health policy
[v] Source: Ministry of Health. National System of Epidemiological Surveillance of Influenza. Season 2017-2018.
[vi] Come on EP, Pape UJ, CurcinV, et al. Efficacy of the influenza vaccine to prevent hospital admission and death without diabetes. CMAJ2016; 188 (14): E342-E351. doi: 10.1503 / cmaj.151059.